Prostatic Adenocarcinoma Clinical Trial
— RPAH2Official title:
Moderate Hypofractionated Radiotherapy (62 Gy in 20 Fractions of 3.1 Gy) Versus Stereotactic Radiotherapy (37.5 Gy in 5 Fractions of 7.5 Gy) With Hyaluronic Acid Injection Between the Prostate and the Rectum for Prostate Cancer of Low- to Intermediate Risk; RPAH2
NCT number | NCT02361515 |
Other study ID # | 2014-846 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2015 |
Est. completion date | January 2020 |
Verified date | March 2022 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present randomized, open, multicentric Phase II trial, in parallel groups with two arms of treatment, compares the treatment A, moderate hypofractionated radiotherapy of 62Gy, to treatment B, stereotactic irradiation of 37.5 Gy with hyaluronic acid injection in the space between the prostate and the rectum to preserve the rectal-wall from high doses of irradiation. The study aims to assess the rates of late urinary toxicities of grade ≥ 2 induced by a moderate hypofractionated radiotherapy (62Gy in 20 fractions of 3.1Gy) and by a stereotactic radiotherapy (37.5Gy in 5 fractions of 7.5Gy), and the rectal toxicities after an injection of hyaluronic acid between the rectal wall and the prostate. Ninety-six patients and 9 centers are included in the protocol.
Status | Completed |
Enrollment | 96 |
Est. completion date | January 2020 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - age superior or equal to 18 years and inferior to 80 years. - patient with a low- to intermediate-risk prostate cancer, according to D'Amico classification, for an exclusive irradiation. - prostate cancer histologically proven. - performance index OMS (World Health Organization) of grade 0-2. - indication of external beam radiotherapy validate by the medical commission of the institution. - IPSS (International Prostate Symptom Score < 15/35 (without alpha-blocker). - the signed consent form. Exclusion Criteria: - Rectal surgery antecedents. - prostate resection less than 6 mois. - Involvement of the seminal vesicles or of the capsule on MRI. - patient who can't cooperate during the treatment. - pelvic irradiation antecedents. - antecedents of inflammatory intestinal pathologies. - neoplasia. - patients treated with anti-neoplastic or anti-angiogenic or with other treatments used in rheumatology and which may include methotrexate (in order not to have a radiosensitizing effect). - patients receiving anticoagulant treatment. - other undergoing study that may interfere with the present study. - patient under legal protection measure. - hypersensitivity to hyaluronic acid. - patient with auto-immune disease. - patient receiving immunosuppressive medication. - severe allergies. - history of endocarditis. |
Country | Name | City | State |
---|---|---|---|
France | Clinique Claude Bernard Service de radiothérapie CMCO Claude Bernard | Albi | |
France | Centre Georges Francois Leclerc | Dijon | |
France | Institut Paoli Calmettes | Marseille | |
France | Site Hospitalier Nord Boulevard Jacques Monod | Nantes | |
France | Centre Hospitalier Lyon Sud | Pierre-Bénite | |
France | Institut de Cancérologie de la Loire | St Etienne | |
France | Groupe ONCORAD Clinique Pasteur | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients with late urinary toxicities of grade = 2 after moderate hypofractionated radiotherapy (62Gy in 20 fractions of 3.1Gy) and after stereotactic radiotherapy (37.5Gy in 5 fractions of 7.5Gy). | Late urinary toxicities of grade = 2 assessed using the Common Toxicity Criteria for Adverse Effects ( CTCAE) v 4.0 classification from 3 months to 3 years. | Follow-up at = 3 months after the radiotherapy and up to 3 years. | |
Secondary | Survival rates without biological relapse in both arms. | Survival rates without biological relapse (increase of the PSA (prostate-specific antigen) beyond nadir + 2 ng/ml, using Phoenix definition). | 3 years. | |
Secondary | Evaluation and comparison of the acute urinary and rectal toxicities in both arms. | all toxicities will be listed using Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0. | 3 months: evaluation at 3 months. | |
Secondary | Evaluation and comparison of the sexual preservation rates in both arms. | evaluation and comparison of the sexual preservation rates in both arms using International Index of Erectile Function (IIEF). | 3 years. | |
Secondary | Late rectal toxicities in both arms, for the evaluation of the hyaluronic acid efficacy to preserve the rectal wall in both approaches. | Late rectal toxicities in both arms, for the evaluation of the hyaluronic acid efficacy to preserve the rectal wall in both approaches, using Common Toxicity Criteria for Adverse Effects (CTCAE) 4.0. | 3 years. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01431391 -
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06015321 -
An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma
|
Phase 2 | |
Completed |
NCT03384199 -
Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer
|
Phase 2 | |
Completed |
NCT04063800 -
Prediction of the Risk of Biochemical Relapse After Radical Prostatectomy for Prostate Cancer Using Radomics on Pre-therapeutic MRI
|
||
Active, not recruiting |
NCT01542021 -
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
|
N/A | |
Recruiting |
NCT05498272 -
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
|
Phase 2 |